Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit

Investigative Ophthalmology and Visual Science

Volumn 43, Issue 12, 2002, Pages 3712-3716

  Dajcs, Joseph J ^a   Thibodeaux, Brett A ^a   Girgis, Dalia O ^a   Shaffer, Megan D ^a   Delvisco, Stephen M ^a   O'Callaghan, Richard J ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LSU EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; LYSOSTAPHIN; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFECT; ENDOPHTHALMITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE INFECTION; IMMUNIZATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; RABBIT; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; ANTIBODY FORMATION; COLONY COUNT, MICROBIAL; CORNEAL STROMA; ENDOPHTHALMITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE INFECTIONS, BACTERIAL; IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOTHERAPY; KERATITIS; LYSOSTAPHIN; METHICILLIN; METHICILLIN RESISTANCE; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VITREOUS BODY;

EID: 0036906020     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107:1497-1502.
2. Ormerod LD, Hertzmark E, Gomez DS, Stabiner RG, Schanzlin DJ, Smith RE. Epidemiology of microbial keratitis in southern California: A multivariate analysis. Ophthalmology. 1987;94:1322-1333.
3. Schein OD, Ormerod LD, Barraquer E, et al. Microbiology of contact lens-related keratitis. Cornea. 1989;8:281-285.
4. Meredith TA. Clinical microbiology of infectious endophthalmitis. In: Ryan SJ, ed. Retina. St. Louis: Mosby; 1994;203-221.
5. Jett BD, Parke DW, Booth MC, Gilmore, MS. Host/parasite interactions in bacterial endophthalmitis. In J Med Microbiol Virol Parasitol Infect Dis. 1997;285:341-367.
6. Liesegang TJ. Bacterial and fungal keratitis. In: Kaufman HE, Baron McDonald MB II, eds. The Cornea. Boston: Butterworth-Heinemann, 1998;159-219.
7. Palmer ML, Hyndiuk MD. Contact lens-related infectious keratitis. Int Ophthalmol Clin. 1993;33:23-49.
8. Mao LK, Flynn HW, Miller D, Pflugfelder SC. Endophthalmitis caused by Staphylococcus aureus. Am J Ophthalmol. 1993;116: 584-589.
9. Kattan HM, Flynn HW, Pflugfelder SC, Robertson C, Forster RK. Nosocomial endophthalmitis survey: Current incidence of infection after intraocular surgery. Ophthalmology. 1991;98:227-238.
10. Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the endophthalmitis vitrectomy study. Am J Ophthalmol. 1996;122:1-17.
11. Brumfitt W, Hamilton-Miller J. Methicillin-resistant Staphylococcus aureus. N Engl J Med. 1989;320:1188-1196.
12. O'Brien FG, Pearman JW, Gracey M, Riley TV, Grubb WB. Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak. J Clin Microbiol. 1999;37:2858-2862.
13. Aldridge KE, Gelfand MS, Schiro DD, Barg NL. The rapid emergence of fluoroquinolone-methicillin-resistant Staphylococcus aureus infections in a community hospital. Diagn Microbiol Infect Dis. 1992;15:601-608.
14. Blumberg HM, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Rapid development ciprofloxacin resistance in methicillin-susceptible and resistant Staphylococcus aureus. J Infect Dis. 1991;163:1279-1285.
15. Maffett M, O'Day DM. Ciprofloxacin-resistant bacterial keratitis. Am J Ophthalmol. 1993;115:545-546.
16. Ross J, Abate MA. Topical vancomycin for the treatment of Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus conjunctivitis. DICP Ann Pharmacother. 1990;68:636-642.
17. Wilhelmus KR, Penland RL. Emerging resistance among ocular isolates of gram-positive cocci [ARVO Abstract]. Invest Ophthalmol Vis Sci. 1996;37(3):S877. Abstract nr 4060.
18. Smith MA, Sorenson JA, Lowy FD, Shakin JL, Harrison W, Jakobiec FA. Treatment of experimental methicillin-resistant Staphylococcus epidermidis endophthalmitis with intravitreal vancomycin. Ophthalmology. 1986;93:1328-1335.
19. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997;350:1670-1673.
20. Peterson DL. Vancomycin-resistant Staphylococcus aureus. Infect Med. 1999;16:235-238.
21. Fleischer AB, Hoover DL, Khan JA, Parisi JT, Bums RP. Topical vancomycin formulation for methicillin-resistant Staphylococcus epidermidis blepharoconjuctivitis. Am J Ophthalmol. 1986;101: 283-287.
22. Callegan MC, Hill JM, Insler MS, Hobden JA, O'Callaghan RJ. Methicillin-resistant Staphylococcus aureus keratitis in the rabbit: Therapy with ciprofloxacin, vancomycin and cefazolin. Curr Eye Res. 1992;11:1111-1119.
23. Kantzanou M, Tassios T, Tseleni-Kotsovili A, Legakis N, Vatopoulos AC. Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1999;43:729-731.
24. Martin RR, White A. The selective activity of lysostaphin in vivo. J Lab Clin Med. 1967;70:1-8.
25. Dixon RE, Goodman JS, Koenig MG. Lysostaphin: An enzymatic approach to staphylococcal disease. III: Combined lysostaphinmethicillin therapy of established staphylococcal abscesses in mice. Yale J Biol Med. 1968;41:62-68.
26. Browder HP, Zygmunt WA, Young JR, Tavorina PA. Lysostaphin: Enzymatic mode of action. Biochem Biophys Res Commun. 1965;19:383-389.
27. Zygmunt WA, Tavormina PA. Lysostaphin: Model for a specific enzymatic approach to infectious disease. Prog Drug Res. 1972;16:309-333.
28. Schindler CA, Schuhart VT. Lysostaphin: A new bacteriolytic agent for the Staphylococcus. Proc Natl Acad Sci USA. 1965;51:414-421.
29. Sloan GL, Robinson JM, Kloos WE. Identification of "Staphylococcus staphylolyticus" NRRL B-2628 as biovar of Staphylococcus simulans. Int J Bacteriol. 1982;32:170-174.
30. Harris RL, Nunnery AW, Riley HD. Effects of lysostaphin on staphylococcal carriage in infants and children. Antimicrob Agents Chemother. 1967;110-112.
31. Heinrich P, Rosenstein R, Bohmer M, Sonner P, Gotz F. The molecular organization of the lysostaphin gene and its sequences repeated in tandem. Mol Gen Genet. 1987;209:563-569.
32. Bramley AJ, Foster R. Effects of lysostaphin on Staphylococcus aureus infections of the mouse mammary gland. Res Vet Sci. 1990;49:120-121.
33. Stark FR, Thornsvard C, Flannery EP, Artestein MS. Systemic lysostaphin in man: Apparent antimicrobial activity in a neutropenic patient. N Engl J Med. 1974;291:239-241.
34. Quickel KE, Selden R, Caldwell JR, Nora NF, Schaffner W. Efficacy and safety of topical lysostaphin treatment of persistent nasal carriage of Staphylococcus aureus. Appl Microbiol. 1971;22:446-450.
35. Climo MW, Patron RL, Goldstein BP, Archer GL. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob Agents Chemother. 1998;42:1355-1360.
36. Huber M, Huber TW. Susceptibility of methicillin-resistant Staphylococcus aureus to lysostaphin. J Clin Microbiol. 1989;27:1122-1124.
37. Polak J, Latta PD, Blackburn P. In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis. 1993;17:265-270.
38. Dajcs JJ, Hume EB, Moreau JM, Caballero AR, Cannon BM, O'Callaghan RJ. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. Invest Ophthalmol Vis Sci. 2000;41:1432-1437.
39. Dajcs JJ, Hume EBH, Zheng XD, Thibodeaux BA, Sloop GD, O'Callaghan RJ. Lysostaphin is effective in treating methicillinresistant Staphylococcus aureus endophthalmitis in the rabbit. Curr Eye Res. 2001;22:451-457.
40. Callegan MC, Engel LS, Hill JM, O'Callaghan RJ. Corneal virulence of Staphylococcus aureus: Roles of alpha-toxin and protein A in pathogenesis. Infect Immun. 1994;62:2478-2482.
41. Schaffner W, Melly MA, Koenig MG. Lysostaphin: An enzymatic approach to staphylococcal disease. II: in vivo studies. Yale J Biol Med. 1967;39:230-244.